Skip to main content
Top
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Chemokine receptor expression in tumour islets and stroma in non-small cell lung cancer

Authors: Chandra M Ohri, Aarti Shikotra, Ruth H Green, David A Waller, Peter Bradding

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

We have previously demonstrated that tumour islet infiltration by macrophages is associated with extended survival (ES) in NSCLC. We therefore hypothesised that patients with improved survival would have high tumour islet expression of chemokine receptors known to be associated with favourable prognosis in cancer. This study investigated chemokine receptor expression in the tumour islets and stroma in NSCLC.

Methods

We used immunohistochemistry to identify cells expressing CXCR1, CXCR2, CXCR3, CXCR4, CXCR5 and CCR1 in the tumour islets and stroma in 20 patients with surgically resected NSCLC. Correlations were made with macrophage and mast cell expression.

Results

There was increased expression of CXCR2, CXCR3, and CCR1 in the tumour islets of ES compared with poor survival (PS) patients (p = 0.007, 0.01, and 0.002, respectively). There was an association between 5 year survival and tumour islet CXCR2, CXCR3 and CCR1 density (p = 0.02, 0.003 and <0.001, respectively) as well as stromal CXCR3 density (p = 0.003). There was a positive correlation between macrophage density and CXCR3 expression (rs = 0.520, p = 0.02) and between mast cell density and CXCR3 expression (rs = 0.499, p = 0.03) in the tumour islets.

Conclusion

Above median expression of CXCR2, CXCR3 and CCR1 in the tumour islets is associated with increased survival in NSCLC, and expression of CXCR3 correlates with increased macrophage and mast cell infiltration in the tumour islets.
Appendix
Available only for authorised users
Literature
1.
go back to reference Welsh TJ, Green RH, Richardson D, Waller DA, O'Byrne KJ, Bradding P: Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol. 2005, 23 (35): 8959-8967. 10.1200/JCO.2005.01.4910.CrossRefPubMed Welsh TJ, Green RH, Richardson D, Waller DA, O'Byrne KJ, Bradding P: Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol. 2005, 23 (35): 8959-8967. 10.1200/JCO.2005.01.4910.CrossRefPubMed
2.
go back to reference Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P: Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J. 2009, 33 (1): 118-126. 10.1183/09031936.00065708.CrossRefPubMed Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P: Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J. 2009, 33 (1): 118-126. 10.1183/09031936.00065708.CrossRefPubMed
3.
go back to reference Rossi D, Zlotnik A: The Biology of Chemokines and their Receptors. Annual Review of Immunology. 2000, 18 (1): 217-242. 10.1146/annurev.immunol.18.1.217.CrossRefPubMed Rossi D, Zlotnik A: The Biology of Chemokines and their Receptors. Annual Review of Immunology. 2000, 18 (1): 217-242. 10.1146/annurev.immunol.18.1.217.CrossRefPubMed
4.
go back to reference Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25 (12): 677-686. 10.1016/j.it.2004.09.015.CrossRefPubMed Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25 (12): 677-686. 10.1016/j.it.2004.09.015.CrossRefPubMed
5.
go back to reference Allavena P, Garlanda C, Borrello MG, Sica A, Mantovani A: Pathways connecting inflammation and cancer. Curr Opin Genet Dev. 2008, 18 (1): 3-10. 10.1016/j.gde.2008.01.003.CrossRefPubMed Allavena P, Garlanda C, Borrello MG, Sica A, Mantovani A: Pathways connecting inflammation and cancer. Curr Opin Genet Dev. 2008, 18 (1): 3-10. 10.1016/j.gde.2008.01.003.CrossRefPubMed
6.
go back to reference Balkwill F: Cancer and the chemokine network. Nat Rev Cancer. 2004, 4 (7): 540-550. 10.1038/nrc1388.CrossRefPubMed Balkwill F: Cancer and the chemokine network. Nat Rev Cancer. 2004, 4 (7): 540-550. 10.1038/nrc1388.CrossRefPubMed
7.
go back to reference Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM: The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med. 2003, 167 (12): 1676-1686. 10.1164/rccm.200301-071OC.CrossRefPubMed Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM: The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med. 2003, 167 (12): 1676-1686. 10.1164/rccm.200301-071OC.CrossRefPubMed
8.
go back to reference Moran CJ, Arenberg DA, Huang CC, Giordano TJ, Thomas DG, Misek DE, et al: RANTES Expression Is a Predictor of Survival in Stage I Lung Adenocarcinoma. Clin Cancer Res. 2002, 8 (12): 3803-3812.PubMed Moran CJ, Arenberg DA, Huang CC, Giordano TJ, Thomas DG, Misek DE, et al: RANTES Expression Is a Predictor of Survival in Stage I Lung Adenocarcinoma. Clin Cancer Res. 2002, 8 (12): 3803-3812.PubMed
9.
go back to reference Zhu YM, Webster SJ, Flower D, Woll PJ: Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Br J Cancer. 2004, 91 (11): 1970-1976. 10.1038/sj.bjc.6602227.CrossRefPubMedPubMedCentral Zhu YM, Webster SJ, Flower D, Woll PJ: Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Br J Cancer. 2004, 91 (11): 1970-1976. 10.1038/sj.bjc.6602227.CrossRefPubMedPubMedCentral
10.
go back to reference Smith DR, Polverini PJ, Kunkel SL, Orringer MB, Whyte RI, Burdick MD, et al: Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med. 1994, 179 (5): 1409-1415. 10.1084/jem.179.5.1409.CrossRefPubMed Smith DR, Polverini PJ, Kunkel SL, Orringer MB, Whyte RI, Burdick MD, et al: Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med. 1994, 179 (5): 1409-1415. 10.1084/jem.179.5.1409.CrossRefPubMed
11.
go back to reference Yuang ANG, Yang PC, Yu CJ, Chen WJ, Lin FY, Kuo SH, et al: Interleukin-8 Messenger Ribonucleic Acid Expression Correlates with Tumor Progression, Tumor Angiogenesis, Patient Survival, and Timing of Relapse in Non-Small-Cell Lung Cancer. Am J Respir Crit Care Med. 2000, 162 (5): 1957-1963.CrossRef Yuang ANG, Yang PC, Yu CJ, Chen WJ, Lin FY, Kuo SH, et al: Interleukin-8 Messenger Ribonucleic Acid Expression Correlates with Tumor Progression, Tumor Angiogenesis, Patient Survival, and Timing of Relapse in Non-Small-Cell Lung Cancer. Am J Respir Crit Care Med. 2000, 162 (5): 1957-1963.CrossRef
12.
go back to reference Masuya D, Huang C, Liu D, Kameyama K, Hayashi E, Yamauchi A, et al: The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients. Cancer. 2001, 92 (10): 2628-2638. 10.1002/1097-0142(20011115)92:10<2628::AID-CNCR1616>3.0.CO;2-F.CrossRefPubMed Masuya D, Huang C, Liu D, Kameyama K, Hayashi E, Yamauchi A, et al: The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients. Cancer. 2001, 92 (10): 2628-2638. 10.1002/1097-0142(20011115)92:10<2628::AID-CNCR1616>3.0.CO;2-F.CrossRefPubMed
13.
go back to reference Keane MP, Belperio JA, Xue YY, Burdick MD, Strieter RM: Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol. 2004, 172 (5): 2853-2860.CrossRefPubMed Keane MP, Belperio JA, Xue YY, Burdick MD, Strieter RM: Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol. 2004, 172 (5): 2853-2860.CrossRefPubMed
14.
go back to reference Wendel M, Galani IE, Suri-Payer E, Cerwenka A: Natural Killer Cell Accumulation in Tumors Is Dependent on IFN-{gamma} and CXCR3 Ligands. Cancer Res. 2008, 68 (20): 8437-8445. 10.1158/0008-5472.CAN-08-1440.CrossRefPubMed Wendel M, Galani IE, Suri-Payer E, Cerwenka A: Natural Killer Cell Accumulation in Tumors Is Dependent on IFN-{gamma} and CXCR3 Ligands. Cancer Res. 2008, 68 (20): 8437-8445. 10.1158/0008-5472.CAN-08-1440.CrossRefPubMed
15.
go back to reference Brightling CE, Kaur D, Berger P, Morgan AJ, Wardlaw AJ, Bradding P: Differential expression of CCR3 and CXCR3 by human lung and bone marrow-derived mast cells: implications for tissue mast cell migration. J Leukoc Biol. 2005, 77 (5): 759-766. 10.1189/jlb.0904511.CrossRefPubMed Brightling CE, Kaur D, Berger P, Morgan AJ, Wardlaw AJ, Bradding P: Differential expression of CCR3 and CXCR3 by human lung and bone marrow-derived mast cells: implications for tissue mast cell migration. J Leukoc Biol. 2005, 77 (5): 759-766. 10.1189/jlb.0904511.CrossRefPubMed
16.
go back to reference Newton P, O'Boyle G, Jenkins Y, Ali S, Kirby JA: T cell extravasation: demonstration of synergy between activation of CXCR3 and the T cell receptor. Mol Immunol. 2009, 47 (2-3): 485-492. 10.1016/j.molimm.2009.08.021.CrossRefPubMedPubMedCentral Newton P, O'Boyle G, Jenkins Y, Ali S, Kirby JA: T cell extravasation: demonstration of synergy between activation of CXCR3 and the T cell receptor. Mol Immunol. 2009, 47 (2-3): 485-492. 10.1016/j.molimm.2009.08.021.CrossRefPubMedPubMedCentral
17.
go back to reference Takanami I, Takeuchi K, Giga M: The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. J Thorac Cardiovasc Surg. 2001, 121 (6): 1058-1063. 10.1067/mtc.2001.113026.CrossRefPubMed Takanami I, Takeuchi K, Giga M: The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. J Thorac Cardiovasc Surg. 2001, 121 (6): 1058-1063. 10.1067/mtc.2001.113026.CrossRefPubMed
18.
go back to reference Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J, et al: Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer. 2002, 35 (1): 23-28. 10.1016/S0169-5002(01)00292-6.CrossRefPubMed Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J, et al: Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer. 2002, 35 (1): 23-28. 10.1016/S0169-5002(01)00292-6.CrossRefPubMed
19.
go back to reference Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, et al: Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med. 1996, 184 (3): 981-992. 10.1084/jem.184.3.981.CrossRefPubMed Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, et al: Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med. 1996, 184 (3): 981-992. 10.1084/jem.184.3.981.CrossRefPubMed
20.
go back to reference Addison CL, Arenberg DA, Morris SB, Xue YY, Burdick MD, Mulligan MS, et al: The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum Gene Ther. 2000, 11 (2): 247-261. 10.1089/10430340050015996.CrossRefPubMed Addison CL, Arenberg DA, Morris SB, Xue YY, Burdick MD, Mulligan MS, et al: The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum Gene Ther. 2000, 11 (2): 247-261. 10.1089/10430340050015996.CrossRefPubMed
21.
go back to reference Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Strom SR, Burdick MD, et al: Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines. Cancer Immunol Immunother. 2000, 49 (2): 63-70. 10.1007/s002620050603.CrossRefPubMed Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Strom SR, Burdick MD, et al: Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines. Cancer Immunol Immunother. 2000, 49 (2): 63-70. 10.1007/s002620050603.CrossRefPubMed
22.
go back to reference Matsuda A, Fukuda S, Matsumoto K, Saito H: Th1/Th2 cytokines reciprocally regulate in vitro pulmonary angiogenesis via CXC chemokine synthesis. Am J Respir Cell Mol Biol. 2008, 38 (2): 168-175. 10.1165/rcmb.2007-0162OC.CrossRefPubMed Matsuda A, Fukuda S, Matsumoto K, Saito H: Th1/Th2 cytokines reciprocally regulate in vitro pulmonary angiogenesis via CXC chemokine synthesis. Am J Respir Cell Mol Biol. 2008, 38 (2): 168-175. 10.1165/rcmb.2007-0162OC.CrossRefPubMed
23.
go back to reference Reckamp KL, Figlin RA, Burdick MD, Dubinett SM, Elashoff RM, Strieter RM: CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer. BMC Cancer. 2009, 9: 213-10.1186/1471-2407-9-213.CrossRefPubMedPubMedCentral Reckamp KL, Figlin RA, Burdick MD, Dubinett SM, Elashoff RM, Strieter RM: CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer. BMC Cancer. 2009, 9: 213-10.1186/1471-2407-9-213.CrossRefPubMedPubMedCentral
24.
go back to reference Yanagawa J, Walser TC, Zhu LX, Hong L, Fishbein MC, Mah V, et al: Snail Promotes CXCR2 Ligand-Dependent Tumor Progression in Non-Small Cell Lung Carcinoma. Clin Cancer Res. 2009, 15 (22): 6820-9. 10.1158/1078-0432.CCR-09-1558.CrossRefPubMedPubMedCentral Yanagawa J, Walser TC, Zhu LX, Hong L, Fishbein MC, Mah V, et al: Snail Promotes CXCR2 Ligand-Dependent Tumor Progression in Non-Small Cell Lung Carcinoma. Clin Cancer Res. 2009, 15 (22): 6820-9. 10.1158/1078-0432.CCR-09-1558.CrossRefPubMedPubMedCentral
Metadata
Title
Chemokine receptor expression in tumour islets and stroma in non-small cell lung cancer
Authors
Chandra M Ohri
Aarti Shikotra
Ruth H Green
David A Waller
Peter Bradding
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-172

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine